Efbemalenograstim alfa

Efbemalenograstim alfa (F 627) is a recombinant fusion protein. Efbemalenograstim alfa is a long acting dimeric granulocyte colony-stimulating factor (G-CSF) that contains two human G-CSF fused to a human immunoglobulin G2 (hIgG2) -Fc fragment with a peptide linker. Efbemalenograstim alfa induces the production of white blood cells[1].

Product Specifications

CAS Number

[2200269-79-8]

Product Name Alternative

Benegrastim; Bineuta; F 627

UNSPSC

12352203

Target

STAT

Type

Inhibitory Antibodies

Related Pathways

JAK/STAT Signaling; Stem Cell/Wnt

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/efbemalenograstim-alfa.html

Purity

97.68

Solubility

10 mM in DMSO

Smiles

[Efbemalenograstimalfa]

Molecular Weight

(89.24 kDa)

References & Citations

[1]Daley W, et, al. Evive successfully concludes first phase III clinical trial of F-627 for chemotherapy-induced neutropenia and met primary endpoints. Shanghai, China: Evive Biotech; January 25, 2018.|[2]Hu Z T, et al. F-627, a G-CSF Dimer, Stimulated a More Rapid Neutrophil Recovery In Cyclophosphamide-Treated Monkeys Compared to Monomer Rhg-CSFs[J]. Blood, 2010, 116 (21) : 1485.|[3]Blair HA. Efbemalenograstim Alfa: First Approval. Drugs. 2023 Aug;83 (12) :1125-1130.